GHRP-2

01 · What it is

GHRP-2 is a synthetic hexapeptide and an agonist at the growth hormone secretagogue receptor GHS-R1a, developed as a successor to GHRP-6 within a family of growth hormone-releasing peptides characterised from the late 1980s onward ^1,2. Investigators describing it and hexarelin together called them superanalogues of GHRP-6 ⁴ — more potent versions of the compound that established the class.

The potency claim is not marketing. In the comparative pharmacology that defined this family, GHRP-2 displayed higher potency on growth hormone release than either GHRP-6 or ipamorelin, both of which were themselves effective ³. GHRP-2 is, on the available evidence, the most potent growth hormone releaser among the compounds in this family.

It is also among the least studied as a treatment. Thirty years of human endocrine pharmacology exist — dose-response work, comparison studies against related hexapeptides, characterisation of the hormonal profile it produces ^1,2,4 — and no efficacy trial in any clinical indication was identified in the indexed literature during preparation of this guide. The compound’s modern appearances are almost entirely in anti-doping analytical chemistry ^7,8 and in reviews describing patterns of unsupervised use ^9,10,13,15.

That combination is the thing worth understanding about GHRP-2. It is not an understudied compound in the sense that BPC-157 is understudied: its pharmacology in humans is well characterised. What it lacks is any test of whether that pharmacology helps anyone.

Unlike ipamorelin, GHRP-2 is not selective. It stimulates adrenocorticotropic hormone, cortisol and prolactin alongside growth hormone ^1,2,3.

As of September 2026 GHRP-2 holds no marketing authorisation from any regulator.

02 · Evidence at a glance

Evidence grade

Early Clinical — human pharmacology established; no efficacy trial

Structure

Synthetic hexapeptide, growth hormone-releasing peptide family ^1,2

Molecular target

Growth hormone secretagogue receptor GHS-R1a ⁵

Potency on growth hormone release

Higher than GHRP-6 and ipamorelin ³

Selectivity

Not selective — releases ACTH, cortisol and prolactin alongside growth hormone ^1,2

Human endocrine studies

Multiple, from the 1990s onward ^1,2,4

Efficacy trials in any clinical indication

None identified

Human pharmacokinetic data

Metabolite profiling after nasal administration ⁷; no full pharmacokinetic profile identified

Detection in athlete samples

Established ⁸

FDA compounding status

Active category 2, 503B, since 29 September 2023 ¹⁶

Approval status

None, any jurisdiction

03 · Mechanism of action

GHS-R1a agonism, and a partly separate pathway from GHRH

GHRP-2 acts at the growth hormone secretagogue receptor rather than the GHRH receptor. The consequence, established across the family, is that growth hormone-releasing peptides act through a route that is partly independent of GHRH — involving both stimulation of endogenous GHRH release and withdrawal of somatostatin tone — which is why combined GHRH plus GHRP administration produces a larger response than either component alone ^1,2. That synergy is a genuine, reproducible pharmacological finding and it is the mechanistic basis for the combination protocols discussed elsewhere in this family.

Potency without selectivity

The design trajectory of this family ran in two directions at once: toward greater potency, and toward greater selectivity. GHRP-2 represents the first. In conscious swine, ipamorelin and GHRP-6 released growth hormone with comparable potency, and GHRP-2 displayed higher potency than either ³. What GHRP-2 did not achieve is the separation of growth hormone release from adrenocorticotropic hormone, cortisol and prolactin release, which the same body of work established as a property of the earlier hexapeptides and which ipamorelin was subsequently engineered to avoid ^1,2,3.

A compound that raises cortisol while raising growth hormone is working against itself on the body composition endpoints it is used for. That is not a hypothetical objection — it follows directly from the endocrine profile the characterisation studies measured.

The endocrine profile in humans

Studies in human volunteers compared the endocrine activity of hexarelin, GHRP-2 and a synthetic octapeptide analogue, reporting similar activities and similar time to peak response across the three ⁴.

Human endocrine pharmacology for this compound is genuinely well described. It is the layer above — what the hormonal changes accomplish — that has never been examined.

An unresolved receptor question in the family

The receptor account for these peptides is less settled than it appears. In humans, the putative antagonist D-Lys-GHRP-6 failed to modify the endocrine response to either acylated ghrelin or hexarelin ⁶, which complicates a simple single-receptor model for the family and applies to GHRP-2 by extension. No study has resolved this for GHRP-2 specifically.

04 · Key research findings

Comparative potency. In the study that characterised ipamorelin, GHRP-2 displayed higher potency than both ipamorelin and GHRP-6 on growth hormone release in conscious swine, while ipamorelin was distinguished by the absence of adrenocorticotropic and cortisol release that GHRP-2 and GHRP-6 produced ³.

The clearest head-to-head data in the family, and the source of GHRP-2’s reputation.

Human endocrine activity. GHRP-2 was studied in humans alongside hexarelin and Tyr-Ala-hexarelin, with the three showing comparable endocrine activities and comparable mean time to peak response ⁴. Broader reviews of the family document its growth hormone-releasing activity across species and administration routes ^1,2.

Well-characterised, reproducible pharmacology.

Diagnostic and combined testing context. The growth hormone-releasing peptides were investigated as diagnostic probes and in combination with GHRH, work that established the synergy between the two receptor systems ^1,2.

GHRP-2 sits within that literature rather than being its main subject.

Efficacy trials. None identified. A search of the indexed literature for this guide found no randomised controlled trial, and no uncontrolled clinical study, evaluating GHRP-2 for any treatment indication.

This is the central finding of the guide, and it stands in contrast to ibutamoren and ipamorelin, both of which were taken into controlled trials and both of which failed. GHRP-2 has not been given the opportunity to fail.

Anti-doping chemistry. Urinary metabolites of GHRP-2 were characterised alongside GHRP-1, GHRP-6, hexarelin and ipamorelin following nasal administration to volunteers ⁷, and GHRP-2 has been detected in urine samples from athletes ⁸.

The most recent human administration data for this compound were generated to detect it.

How the wider literature positions it. Reviews of growth hormone secretagogue safety and efficacy ⁹, of secretagogues in body composition management ¹⁰, and recent syntheses in sports medicine and endocrinology ^{11,12,13,14,15} include GHRP-2 among compounds with established endocrine activity and no validated clinical outcomes.

Independent reviewers describe the same gap.

05 · Evidence overview

06 · Safety profile

Endocrine profile as the primary safety consideration. GHRP-2 stimulates adrenocorticotropic hormone, cortisol and prolactin alongside growth hormone ^1,2,3. Sustained elevation of cortisol has well-established consequences, and elevated prolactin has its own. Neither has been characterised under repeated GHRP-2 administration in humans, because no such study exists.

Class liability. Growth hormone antagonises insulin action, and glucose tolerance is the principal metabolic consideration for every effective secretagogue ^9,10.

Human data. Confined to acute endocrine response studies and volunteer administration for metabolite characterisation ^4,7. There is no controlled safety dataset of any duration.

What is genuinely unknown. Everything beyond acute administration. No repeat-dose human study, so nothing is known about cortisol or prolactin under sustained dosing — the two effects that most distinguish this compound from ipamorelin. No toxicology programme was identified: no repeat-dose, genotoxicity, reproductive or carcinogenicity data. No immunogenicity assessment. No human pharmacokinetic profile for subcutaneous administration. And, most simply, no evidence about whether any of the hormonal changes it reliably produces translate into an outcome anyone would want.

FDA’s stated basis for placing GHRP-2 in category 2 includes immunogenicity risk from aggregation and peptide-related impurities, the presence of an unnatural amino acid adding complexity to characterisation, and awareness of reports of serious adverse events including increased insulin requirement to maintain blood glucose, death of critically ill study subjects, infection and pancreatitis, with causality not established ¹⁶.

Those reports are not traceable to a primary publication identified during preparation of this guide, and this guide does not assert them as findings. They are recorded here as the regulator’s stated rationale, which is a different kind of claim.

07 · US regulatory status

Current as of 6 September 2026. GHRP-2 is not approved as a drug in the United States or any other jurisdiction, and is not a controlled substance.

Growth hormone releasing peptide-2 was placed in category 2 of FDA’s interim bulk drug substances policy for 503B outsourcing facilities on 29 September 2023, for injectable and nasal routes of administration, and remains in the active category 2 table rather than the withdrawn one ¹⁶. GHRP-2 was not among the seven substances reviewed by the Pharmacy Compounding Advisory Committee in July 2026 ¹⁷.

Under the World Anti-Doping Code, growth hormone secretagogues are prohibited at all times. GHRP-2 has been detected in urine samples from athletes using validated methods ⁸, and metabolite targets for detection are established ⁷. Competitors should consult the current Prohibited List directly rather than rely on secondary summaries, including this one.

08 · Limitations of the evidence

1. No efficacy trial exists, in any indication. Not a negative one, not an underpowered one — none. Every claim about what GHRP-2 achieves is an inference from its endocrine profile.
2. The endocrine profile includes effects that work against the intended use. Cortisol and prolactin release alongside growth hormone ^1,2,3 is the reason ipamorelin was developed. A compound used for body composition that also raises cortisol has an internal contradiction that no study has quantified.
3. Potency is not benefit. GHRP-2 being the most potent growth hormone releaser in the family ³ establishes a pharmacological ranking, not a clinical one. Ibutamoren raised IGF-1 decisively in a controlled trial and improved nothing functional; potency and outcome are separable, and in this family they have separated.
4. All human data are acute. Endocrine response studies and single-administration metabolite work ^4,7. Nothing addresses repeated dosing over days, weeks or months, which is how the compound is used.
5. No toxicology programme was identified, in any species: no repeat-dose, genotoxicity, reproductive or carcinogenicity data.
6. The receptor model has an unresolved complication. A putative antagonist failed to block the endocrine response to related compounds in humans ⁶, which the literature has not reconciled.
7. The regulator’s adverse event summary cannot be traced to a primary publication. FDA describes serious events including deaths in critically ill subjects ¹⁶; no source study was identified. This guide reports the rationale as a regulatory position and not as a finding, and the gap should be closed before anyone relies on it in either direction.

09 · References

1. Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides. Eur J Endocrinol. 1997;136(5):445–460.

   PMID 9186261 ↗

2. Camanni F, Ghigo E, Arvat E. Growth hormone-releasing peptides and their analogs. Front Neuroendocrinol. 1998;19(1):47–72.

   PMID 9465289 ↗

3. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561.

   PMID 9849822 ↗

4. Arvat E, Di Vito L, Lanfranco F, et al. Tyr-Ala-hexarelin, a synthetic octapeptide, possesses the same endocrine activities of hexarelin and GHRP-2 in humans. J Endocrinol Invest. 1999;22(2):91–97.

   PMID 10195374 ↗

5. Smith RG. Development of growth hormone secretagogues. Endocr Rev. 2005;26(3):346–360.

   PMID 15814848 ↗

6. Benso A, Prodam F, Lucatello B, et al. d-Lys-GHRP-6 does not modify the endocrine response to acylated ghrelin or hexarelin in humans. Neuropeptides. 2007;41(1):45–49.

   PMID 17112585 ↗

7. Semenistaya E, Zvereva I, Thomas A, Thevis M, Krotov G, Rodchenkov G. Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, hexarelin, and ipamorelin. Drug Test Anal. 2015;7(10):919–925.

   PMID 25869809 ↗

8. Cox HD, Hughes CM, Eichner D. Detection of GHRP-2 and GHRP-6 in urine samples from athletes. Drug Test Anal. 2015;7(5):439–444.

   PMID 25809000 ↗

9. Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45–53.

   PMID 28400207 ↗

10. Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149–S159.

    PMID 32257855 ↗

11. Mayfield CK, Bolia IK, Feingold CL, et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med. 2026;54(1):223–229.

    PMID 41476424 ↗

12. Rahman OF, Lee SJ, Seeds WA. Therapeutic peptides in orthopaedics: applications, challenges, and future directions. J Am Acad Orthop Surg Glob Res Rev. 2026;10(1):e25.00236.

    PMID 41490200 ↗

13. Coutinho LFD, de Oliveira Neves LF, Camilo RP. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. J Sports Med Phys Fitness. 2026;66(7):880–885.

    PMID 41880199 ↗

14. Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026;56(8):1921–1935.

    PMID 41966639 ↗

15. Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475.

    PMID 42395176 ↗

16. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Page current as of 22 April 2026. Regulatory document; no PMID.

    Source ↗

17. US Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Docket FDA-2025-N-6895. Regulatory document; no PMID.

    Source ↗